Bill Rastetter

Track

Insider profile

Currently holds positions in Neurocrine Biosciences Inc, Fate Therapeutics Inc, Regulus Therapeutics Inc and Dare Bioscience Inc

Performance

Overall performance
3.0
Performance over holding periods
3.0
30 days 90 days 120 days
Average return 2% 8.2% 15.1%
Success rate 43% 68% 82%
Transactions
7 14% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Chairman of the Board Neurocrine Biosciences Inc May 1, 2011 -
Independent Chairman of the Board Fate Therapeutics Inc Nov. 1, 2011 -
Independent Director Regulus Therapeutics Inc April 1, 2013 -
Lead Independent Director Dare Bioscience Inc None -
Independent Chairman of the Board Illumina Inc Jan. 27, 2005 - Jan. 28, 2016
Bill Rastetter's trades of Neurocrine Biosciences Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-11-06 2025-11-05
PlS Planned sale
7,574 -45.1%
376.00
US$747,180 		7,574 -45.1% 376.00 US$747,180
2025-11-05 2025-11-05
PrS Proposed sale
72,180
304.88
US$4,433,607 		72,180 304.88 US$4,433,607
2025-05-07 2025-05-05
PlS Planned sale
2,830 -1.7%
205.22
US$2,736,333 		2,830 -1.7% 205.22 US$2,736,333
2025-05-05 2025-05-05
PrS Proposed sale
30,000
109.68
US$3,290,400 		30,000 109.68 US$3,290,400
2024-08-16 2024-08-15
S Sale
14,250 -27.5%
146.69
US$2,090,332 		14,250 -27.5% 146.69 US$2,090,332
2024-01-04 2024-01-02
PlS Planned sale
11,044 -17.6%
131.47
US$1,451,927 		11,044 -17.6% 131.47 US$1,451,927
2024-01-02 2024-01-02
PrS Proposed sale
11,044
131.76
US$1,455,157 		11,044 131.76 US$1,455,157
2023-05-03 2023-05-01
PlS Planned sale
4,300 -9.1%
101.43
US$436,135 		4,300 -9.1% 101.43 US$436,135
2023-05-01 2023-05-01
PrS Proposed sale
4,300
101.04
US$434,472 		4,300 101.04 US$434,472
2023-04-21 2023-04-21
PlS Planned sale
6,034 -13.3%
105.04
US$633,787 		6,034 -13.3% 105.04 US$633,787
2023-04-21 2023-04-19
PlS Planned sale
903 -2.5%
105.00
US$94,819 		903 -2.5% 105.00 US$94,819
2023-04-19 2023-04-19
PrS Proposed sale
11,216
103.72
US$1,163,324 		11,216 103.72 US$1,163,324
2022-04-05 2022-04-01
PlS Planned sale
10,728 -24.0%
94.93
US$1,018,366 		10,728 -24.0% 94.93 US$1,018,366
2019-05-08 2019-05-07
B Purchase
92,889 +151.4%
1.08
US$100,320 		92,889 +151.4% 1.08 US$100,320
2017-07-25 2017-07-25
B Purchase
274,725 +78.5%
0.91
US$250,000 		274,725 +78.5% 0.91 US$250,000
2017-03-07 2017-03-07
B Purchase
250,000 +250.0%
1.15
US$287,500 		250,000 +250.0% 1.15 US$287,500
2004-05-26 2004-05-24
US Biogen Inc (BIIB)
S Sale
29,081 -26.9%
62.51
US$1,817,714 		29,081 -26.9% 62.51 US$1,817,714
2004-05-20 2004-05-19
US Biogen Inc (BIIB)
S Sale
25,000 -18.8%
60.03
US$1,500,750 		25,000 -18.8% 60.03 US$1,500,750
2004-05-06 2004-05-04
US Biogen Inc (BIIB)
S Sale
25,000 -13.5%
58.83
US$1,470,750 		25,000 -13.5% 58.83 US$1,470,750
2004-05-06 2004-05-04
US Biogen Inc (BIIB)
S Sale
80,000 -47.2%
58.68
US$4,694,400 		80,000 -47.2% 58.68 US$4,694,400
2004-05-06 2004-05-04
US Biogen Inc (BIIB)
S Sale
25,000 -12.8%
58.83
US$1,470,750 		25,000 -12.8% 58.83 US$1,470,750